Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

Completed

Conditions studied: Multiple Sclerosis, Relapsing-Remitting

In brief

A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.

Key facts

Study ID

NCT01158183

Run by

Bayer

People needed

226

Starts

2007-07-01

Expected to finish

2009-09-01

Last updated by the study team

2010-07-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provides written informed consent to participate in the study
• At least 18 but no more than 65 years old
• Documented clinical diagnosis of a relapsing form of multiple sclerosis or confirmed clinically isolated syndrome (CIS)
• Initiating Betaseron therapy, or resuming Betaseron after not having used it for at least three months
• Willing and able to provide a valid e-mail address which will be in use for the duration of the study
• Willing and able to complete study questionnaires via the Internet
• Has reliable Internet access for the duration of the study
• Completes the baseline patient questionnaire

You may not qualify if…

• Kurtzke Expanded Disability Status Scale (EDSS) score greater than 6.0
• Cognitive dysfunction that, in the Investigator's judgment, raises doubts about the study participant's ability to provide informed consent or accurately complete the monthly patient questionnaire
• Any use of Betaseron within the three months prior to study entry
• Inability to read, write, or speak the English language
• Illness or disease other than multiple sclerosis that the Investigator believes is likely to cause the patient's death or incapacity within twelve months
• Any severe, uncontrolled illness or condition that the Investigator believes could dominate the patient's quality of life
• Coexistent autoimmune disease such as rheumatoid arthritis, lupus, or psoriasis that is likely to be exacerbated by treatment with Interferon
• Current use of any immunosuppressive medication
• Previous participation in a multiple sclerosis (MS) clinical trial within the three months prior to study entry
• Previous use of monoclonal antibodies treating MS within the three months prior to study entry
• Current use of any secondary treatment for multiple sclerosis other than the episodic use of steroids during relapses or exacerbations

Where it is running

• Study site — Many Locations, Alabama, United States
• Study site — Many Locations, California, United States
• Study site — Many Locations, Colorado, United States
• Study site — Many Locations, Florida, United States
• Study site — Many Locations, Illinois, United States
• Study site — Many Locations, Iowa, United States
• Study site — Many Locations, Kansas, United States
• Study site — Many Locations, Louisiana, United States
• Study site — Many Locations, Maine, United States
• Study site — Many Locations, Massachusetts, United States
• Study site — Many Locations, Michigan, United States
• Study site — Many Locations, Missouri, United States
• Study site — Many Locations, Nevada, United States
• Study site — Many Locations, New Hampshire, United States
• Study site — Many Locations, New Jersey, United States
• Study site — Many Locations, New York, United States
• Study site — Many Locations, North Carolina, United States
• Study site — Many Locations, North Dakota, United States
• Study site — Many Locations, Ohio, United States
• Study site — Many Locations, Oregon, United States
• Study site — Many Locations, Pennsylvania, United States
• Study site — Many Locations, Rhode Island, United States
• Study site — Many Locations, Tennessee, United States
• Study site — Many Locations, Texas, United States
• Study site — Many Locations, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.